{
    "clinical_study": {
        "@rank": "83778", 
        "arm_group": [
            {
                "arm_group_label": "Women 16  to 26 years of age", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Heterosexual men 16 to 26 years of age", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Men 16 to 26 years of age who have sex with men", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the immunogenicity and tolerability of V503 in 16- to\n      26-year old men and women. The overall goal is to bridge V503 efficacy findings in young\n      women to young men based on the demonstration of similar immunogenicity and safety profiles."
        }, 
        "brief_title": "Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Genital Warts", 
            "Anal Cancer", 
            "Anal Intraepithelial Neoplasia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anus Neoplasms", 
                "Neoplasms", 
                "Condylomata Acuminata", 
                "Carcinoma in Situ"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study participants will be administered a 3-dose regimen of V503. They will be assessed for\n      immunogenicity 1 month following completion of vaccination. All participants will be\n      followed for safety for a total of 12 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Good physical health\n\n          -  Has never had Pap testing (cervical or anal) or has only had normal Pap test results\n\n          -  Other inclusion criteria will be discussed with the investigator\n\n        Exclusion Criteria:\n\n          -  History of severe allergic reaction that required medical intervention\n\n          -  Currently enrolled in a clinical trial\n\n          -  If participant is female, pregnant\n\n          -  Currently immunocompromised or having received immunosuppressive therapy in the last\n             year\n\n          -  Positive test for HPV\n\n          -  History of HPV-related external genital lesions or HPV-related anal lesions or anal\n             cancer\n\n          -  If participant is female, history of abnormal cervical biopsy results\n\n          -  Other exclusion criteria will be discussed with the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "26 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "2500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651949", 
            "org_study_id": "V503-003", 
            "secondary_id": "2012-002758-22"
        }, 
        "intervention": {
            "arm_group_label": [
                "Women 16  to 26 years of age", 
                "Heterosexual men 16 to 26 years of age", 
                "Men 16 to 26 years of age who have sex with men"
            ], 
            "description": "Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6", 
            "intervention_name": "V503 Vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 21, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Geometric mean titers (GMTs) to the HPV types contained in the V503 vaccine", 
                "safety_issue": "No", 
                "time_frame": "Four weeks post vaccination 3"
            }, 
            {
                "measure": "Number of participants with injection-site adverse experiences of erythema, pain, and swelling", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 through Day 5 following any vaccination"
            }, 
            {
                "measure": "Number of participants with elevated body temperature (\u2265100\u00b0 F)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 through Day 5 following any vaccination"
            }
        ], 
        "removed_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Colombia", 
                "Denmark", 
                "Germany", 
                "Israel", 
                "Malaysia", 
                "Mexico", 
                "Philippines", 
                "Norway", 
                "Peru", 
                "Poland", 
                "South Africa", 
                "Spain", 
                "Sweden", 
                "Thailand", 
                "Turkey"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651949"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with seroconversion to the HPV types in the V503 vaccine", 
            "safety_issue": "No", 
            "time_frame": "Four weeks post vaccination 3"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}